#USA #Cambridge #Leap Therapeutics #Sirexatamab #Advanced CRC

Leap Therapeutics to Host Virtual KOL Event

Leap Therapeutics, Inc. is set to host a significant virtual Key Opinion Leader (KOL) event aimed at addressing advanced colorectal cancer treatment. Scheduled for April 23, 2025, at 2:30 PM ET, this event will feature leading oncologist Zev A. Wainberg, MD, who is a Professor of Medicine at the University of California, Los Angeles (UCLA), and co-director of the UCLA GI Oncology Program. Dr. Wainberg will engage in a comprehensive discussion with Leap's Chief Medical Officer, Cynthia Sirard, MD, focusing on the unmet needs in this patient population and how Leap's investigational drug, sirexatamab (DKN-01), might enhance current therapeutic strategies.

Discussion Focus

The KOL event will center around positive findings from Part B of the Phase 2 DeFianCe study, where sirexatamab was tested on second-line patients suffering from advanced microsatellite stable (MSS) colorectal cancer (CRC). In this setting, participants will explore the therapeutic potential of this humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein. This insights sharing is anticipated to enrich understanding of the treatment landscape and the prospective impact of sirexatamab in clinical settings.

The event format will allow for a live question-and-answer session following the expert discussion, ensuring that participants can delve deeper into the topic. Those unable to attend live can find a recorded version available on Leap Therapeutics' Investors page shortly after the event.

Insights into Dr. Zev Wainberg

Dr. Zev A. Wainberg brings extensive experience and credentials as a recognized leader in gastrointestinal oncology. With a strong background in medical oncology and hematology acquired during his training at UCLA, as well as a residency at the Albert Einstein College of Medicine, Wainberg is at the forefront of research in gastrointestinal cancers, which includes areas like pancreatic, colon, gastric, and esophageal cancers. Sirexatamab’s approach to targeting cancer stem cells exemplifies an innovative strategy aimed at improving treatment efficacy through novel therapeutics.

About Leap Therapeutics

Founded with a mission to develop advanced therapeutics in oncology, Leap Therapeutics (Nasdaq: LPTX) is dedicated to addressing critical treatment gaps for patients. Among its leading clinical candidates is sirexatamab, which has shown promise in targetting DKK1 in patients with colorectal cancer. The company also has another potential candidate, FL-501, which focuses on the growth differentiation factor 15 (GDF-15) protein and is currently undergoing preclinical development.

For ongoing updates and detailed investor information, stakeholders are encouraged to visit Leap Therapeutics' official website and public filings, which can be accessed via the SEC's EDGAR database.

Leap’s commitment to advancing cancer treatment reflects its broader goal of enhancing the quality of life for patients facing these challenging diagnoses. As such, this virtual event is not just a platform for knowledge exchange, but also an opportunity to shape the future of colorectal cancer therapy.

Register for the Event

Interested participants can register for the KOL event through the links provided by Leap Therapeutics. This initiative aligns with the company's broader strategy to foster collaboration and enhance clinical insights within the oncology community.

In conclusion, Leap Therapeutics’ upcoming virtual KOL event signifies an essential step forward for patients grappling with advanced colorectal cancer, highlighting the transformative potential of innovative treatments like sirexatamab.